1. Home
  2. NEGG vs CGEM Comparison

NEGG vs CGEM Comparison

Compare NEGG & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newegg Commerce Inc.

NEGG

Newegg Commerce Inc.

HOLD

Current Price

$20.17

Market Cap

883.1M

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.94

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEGG
CGEM
Founded
2001
2016
Country
United States
United States
Employees
762
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
883.1M
904.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NEGG
CGEM
Price
$20.17
$14.94
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$30.13
AVG Volume (30 Days)
76.5K
784.0K
Earning Date
04-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$5.68
52 Week High
$137.84
$16.74

Technical Indicators

Market Signals
Indicator
NEGG
CGEM
Relative Strength Index (RSI) 21.56 54.01
Support Level N/A $11.92
Resistance Level $47.10 $16.10
Average True Range (ATR) 2.81 0.98
MACD -1.16 0.15
Stochastic Oscillator 5.82 66.07

Price Performance

Historical Comparison
NEGG
CGEM

About NEGG Newegg Commerce Inc.

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: